NET CLINICAL TRIALS IN CANADA

For an up-to-date listing of all active recruiting NET Clinical Trials please visit: Neuroendocrine Tumour Open Trials – Canada

The following information on active Neuroendocrine clinical trials in Canada was taken from the clinicaltrials.gov website.

Click on each trial to go to more information including protocol, objectives, entry criteria, investigators and locations in Canada.

Status Study Title Intervention Locations
Recruiting 68Ga-DOTA-TATE PET/CT Imaging in NETs Diagnostic Test: 68Ga-DOTA-TATE CHUS
Sherbrooke, Quebec, Canada
Recruiting A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours Drug: [177]Lu-DOTA-TATE Cross Cancer Institute
Edmonton, Alberta, Canada
Recruiting 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors Diagnostic Test: 68Ga -DOTATATE PET scans Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Recruiting DOTATOC PET/CT for Imaging NET Patients Diagnostic Test: 68Ga-DOTATOC PET/CT

Diagnostic Test: 18F-FDG PET/CT

BC Cancer
Vancouver, British Columbia, Canada
Recruiting Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors Diagnostic Test: 18F-DOPA with furosemide University of Alberta Hospital
Edmonton, Alberta, Canada
Recruiting Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors Drug: F18-FDG Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Recruiting Personalized PRRT of Neuroendocrine Tumors Drug: 177Lu-Octreotate CHU de Québec – Université Laval
Quebec City, Quebec, Canada
Recruiting A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Drug: CAM2029

Drug: Octreotide LAR

Drug: Lanreotide ATG

Recruiting A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use Drug: [68]Ga-HA-DOTATATE Cross Cancer Institute
Edmonton, Alberta, Canada
Recruiting 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors Drug: 68Ga-HA-DOTATATE University of Alberta
Edmonton, Alberta, Canada
Recruiting Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging Diagnostic Test: 18F-FDG PET/CT

Diagnostic Test: 68Ga-DOTATOC PET/CT

BC Cancer
Vancouver, British Columbia, Canada
Recruiting 18F-DOPA II – PET Imaging Optimization Drug: 18F-DOPA

Drug: Furosemide Injection

WC Mackenzie Health Science Centre / University of Alberta Hospital
Edmonton, Alberta, Canada
Not yet recruiting 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Drug: 177Lu-DOTATOC BC Cancer
Vancouver, British Columbia, Canada
Recruiting Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Drug: Lutetium [177Lu] oxodotreotide/dotatate CHU de Québec – Université Laval
Québec, Canada
Recruiting FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) Drug: [Ga-68]-PNT6555

Drug: [Lu-177]-PNT6555

University Health Network – Princess Margaret Cancer Centre
Toronto, Ontario, CanadaCHUM – Centre hospitalier de l’Université de Montréal
Montréal, Quebec, CanadaJewish General Hospital
Montréal, Quebec, Canada

R2Neuroendocrine Tumour Canada | Open Studies

 Status | Clinical Trials

1 Recruiting Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
Intervention:
2 Recruiting A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Condition: Carcinoma, Neuroendocrine
Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
3 Not yet recruiting Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Intervention: Drug: Lutetium-177 Octreotate
4 Recruiting Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Interventions: Drug: Lanreotide (Autogel formulation);   Drug: Placebo
5 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
6 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

Conditions: Cushing’s Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
7 Recruiting Personalized PRRT of Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
8 Available 18F-FDOPA PET in Neuroendocrine Tumours

Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
9 Unknown  Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Conditions: Renal Cell Carcinoma;   Neuroendocrine Tumours
Intervention: Drug: 18F-FAZA PET Imaging
10 Unknown  123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
11 Recruiting Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

Condition: Neuroendocrine Tumors
Intervention: Other: Gallium-68 DOTA TATE PET scan
12 Not yet recruiting An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis

Condition: Carcinoma, Neuroendocrine
Intervention: Drug: Everolimus

Share This Story, Choose Your Platform!